Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

Newswire.ca - Tue May 12, 7:30AM CDT

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.

USANewsGroup.com News Commentary

VANCOUVER, BC, May 12, 2026 /CNW/ -- Cardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in late April: U.S. heart disease costs are on pace to quadruple by 2050, and total national healthcare spending is already closing in on $5 trillion a year[1]. That kind of structural pressure is forcing hospitals to rethink how they diagnose and treat cardiac patients, and the money is following. The global AI cardiology market, valued at $2.78 billion this year, is projected to reach over $14 billion by 2034 as health systems race to deploy machine learning tools that can cut through diagnostic backlogs[2]. Five companies sit at the center of this convergence: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), BridgeBio Pharma (NASDAQ: BBIO), Bristol Myers Squibb (NYSE: BMY), Arrowhead Pharmaceuticals (NASDAQ: ARWR), and Amgen (NASDAQ: AMGN).

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).